Abstract

TRANSDERMAL PATCHES OF VALSARTAN: FORMULATION AND EVALUATION

Bhawana Sethi, Anil Kumar Sahdev*

Abstract

Transdermal drug delivery system has been seen a veritable explosion in the past decades. In the present scenario, very few transdermal patches are available. Matrix-diffusion type transdermal film of valsartan was designed with various concentration of HPMC (k4M, K15M, K100M). Valsartan is a nonpeptide angiotensin II AT1 receptor antagonist and very well-tolerating hypertension by specifically blocking the action of angiotensin-II on the angiotensin Type-1 receptor. The drug has 23% bioavailability with biological half life of 7.5h. The result of the formulation E was showing weight variation(0.0519 ± 0.0004), percentage moisture absorption (3.45 ± 1.08), percentage moisture loss (4.8 ± 1.14), water vapour transmission rate (0.46 ± 0.015g/hr/cm2), thickness (0.056 ± 0.005mm), Folding endurance (1033.67 ± 7.094), tensile strength (0.379 ± 0.006 kg/mm2). In vitro release studies showed zero-order release from all the patches. The permeation was studies were carried out for 24h showing release up to 39%. Stability studies are carried out for 7 weeks and indicates that drug remain stable for that period and primary irritation studies indicated that the transdermal patches are non irritant.

Keywords: Transdermal patches, Valsartan, HPMC, Hypertension.